There was no benefit of either ESA or increased Hb in an ESA trial on patients with traumatic brain injury [68, 69], and there was no benefit in a phase 3 trial with ESA treatment of stroke patients [70]. The gene discussed is GSTM1; the disease is stroke disorder.